Pages that link to "Q28193118"
Jump to navigation
Jump to search
The following pages link to Pharmacological treatments for acute migraine: quantitative systematic review (Q28193118):
Displaying 50 items.
- Zolmitriptan for acute migraine attacks in adults (Q24194592) (← links)
- Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews (Q24194789) (← links)
- Gabapentin for chronic neuropathic pain and fibromyalgia in adults (Q24194998) (← links)
- Aspirin with or without an antiemetic for acute migraine headaches in adults (Q24197721) (← links)
- Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults (Q24197826) (← links)
- Ibuprofen with or without an antiemetic for acute migraine headaches in adults (Q24197974) (← links)
- Sumatriptan (intranasal route of administration) for acute migraine attacks in adults (Q24203640) (← links)
- Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults (Q24203684) (← links)
- Sumatriptan (oral route of administration) for acute migraine attacks in adults (Q24203707) (← links)
- Ibuprofen with or without an antiemetic for acute migraine headaches in adults (Q24234446) (← links)
- Gabapentin for chronic neuropathic pain and fibromyalgia in adults (Q24235709) (← links)
- Aspirin with or without an antiemetic for acute migraine headaches in adults (Q24235987) (← links)
- Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults (Q24236410) (← links)
- Diagnosis and management of the primary headache disorders in the emergency department setting (Q24651176) (← links)
- Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction (Q25256846) (← links)
- A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine (Q26823673) (← links)
- (Q28167411) (redirect page) (← links)
- Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks (Q28171147) (← links)
- Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms (Q28199015) (← links)
- Patient satisfaction with eletriptan in the acute treatment of migraine in primary care (Q28221721) (← links)
- Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms (Q28222020) (← links)
- Triptans for the management of migraine (Q34129854) (← links)
- Placebo and other psychological interactions in headache treatment (Q34257107) (← links)
- Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine (Q34588506) (← links)
- Real-Time Assessment of the Effect of Biofeedback Therapy with Migraine: A Pilot Study (Q34667894) (← links)
- Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability (Q34691359) (← links)
- Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache (Q35684215) (← links)
- Do placebo response rates from cessation trials inform on strength of addictions? (Q35859923) (← links)
- Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls (Q36013751) (← links)
- Eletriptan in migraine (Q36106757) (← links)
- Methodological issues in systematic reviews of headache trials: adapting historical diagnostic classifications and outcome measures to present-day standards. (Q36161561) (← links)
- Safety and efficacy of eletriptan in the treatment of acute migraine (Q36408742) (← links)
- Eletriptan: a review of its use in the acute treatment of migraine (Q36514170) (← links)
- A review of evidence-based medicine and meta-analytic reviews in migraine (Q36632277) (← links)
- Eletriptan: a review and new perspectives (Q36641480) (← links)
- Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores (Q36757015) (← links)
- Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine (Q36947155) (← links)
- Optimizing prophylactic treatment of migraine: Subtypes and patient matching (Q37052803) (← links)
- Economic evaluation of pharmacotherapy of migraine pain: a review of the literature (Q37641349) (← links)
- Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review (Q37864874) (← links)
- Drug therapy in headache. (Q38511244) (← links)
- Relevance of absorption rate and lag time to the onset of action in migraine (Q39325072) (← links)
- A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. (Q39356859) (← links)
- The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. (Q39384899) (← links)
- Economic and patient-reported outcomes of oral triptans in the treatment of migraine (Q40385073) (← links)
- A new stability indicating HPLC method for related substances in zolmitriptan (Q40965235) (← links)
- Sublingual Delivery of Frovatriptan: An Indication of Potential Alternative Route. (Q42738044) (← links)
- An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan (Q44178639) (← links)
- Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine (Q44655384) (← links)
- Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan (Q45243683) (← links)